Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline
February 26, 2025 07:00 AM Eastern Standard Time HAYWARD, Calif.–(BUSINESS WIRE)–Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to accelerate drug discovery and development, today announced…